Heidi Health secures $65M to drive global growth of its AI scribe platform

Australia-based Heidi Health has secured $65 million in Series B funding to accelerate the global expansion of its AI-powered medical scribe technology, pushing its valuation to $465 million and total capital raised to nearly $100 million.

The round was led by Point72 Private Investments, with continued backing from Headline, Blackbird, and Latitude. The fresh funding will enable Heidi to grow its international presence, strengthen teams in the UK, US, and Canada, and deepen adoption across Europe, Asia, and Africa.

Heidi Health’s platform uses proprietary AI built on Google’s Gemini to automate clinical documentation, capturing notes, generating summaries, and supporting follow-up communication — all while preserving clinician-patient interaction. The company’s expansion plan includes new offices, localised market support, and greater integration with healthcare systems worldwide.

To support this scale-up, Heidi has appointed Paul Williamson (formerly of Plaid) as Chief Revenue Officer and Dr Simon Kos, ex-Microsoft CMO, as Chief Medical Officer. Their addition underscores Heidi’s focus on both commercial growth and clinical integrity.

Investors cite Heidi’s rapid adoption rates as proof of its potential to ease healthcare burdens while maintaining the human touch in care delivery. The company is positioning itself among global peers like Suki and Commure as AI transforms the administrative core of healthcare.

Explore how Heidi Health is redefining medical documentation and reshaping the future of clinical efficiency. Read here.